PSG — PharmaSGP Holding SE Income Statement
0.000.00%
Last trade - 00:00- €282.97m
- €315.12m
- €101.10m
- 98
- 50
- 83
- 94
Annual income statement for PharmaSGP Holding SE, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 62.6 | 63.2 | 65.3 | 85.8 | 101 |
| Cost of Revenue | |||||
| Gross Profit | 56.7 | 57 | 58.9 | 76.8 | 91.6 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 40.2 | 49 | 50.4 | 68.1 | 76.5 |
| Operating Profit | 22.4 | 14.2 | 14.9 | 17.7 | 24.6 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | 22.3 | 14.1 | 14.2 | 15.8 | 21.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 16.7 | 10.6 | 10.7 | 12 | 16.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 16.7 | 10.6 | 10.7 | 12 | 16.4 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 16.7 | 10.6 | 10.7 | 12 | 16.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.41 | 0.992 | 0.995 | 1.11 | 1.39 |
| Dividends per Share |